Science

2021

  • . Comprehensive in vitro characterization of the mechanism of action of EPI-7386, an androgen receptor N-terminal inhibitor. 2021 AACR. (Abstract Number: 1209).

    AACR 2021 Poster Presentation
  • . Preclinical and clinical pharmacology of EPI-7386, an androgen receptor N-terminal domain inhibitor for castration-resistant prostate cancer. ASCO GU 2021. (Abstract Number: 119).

    ASCO-GU Poster Presentation

2020

  • . The preclinical characterization of the N-terminal domain androgen receptor inhibitor, EPI-7386, for the treatment of prostate cancer. ENA 2020 – 32nd Symposium. (EORTC-NCI-AACR) (Abstract ID #181).

    EORTC-NCI-AACR 32nd Symposium Poster
  • . EPI-7386, a potent N-terminal domain androgen receptor inhibitor, with a favorable preclinical safety and superior in vitro/in vivo profile, in clinical development for prostate cancer. Prostate Cancer Foundation 27th Annual Scientific Retreat.

    Prostate Cancer Foundation 27th Annual Scientific Retreat Poster
  • . Pre-clinical profile of EPI-7386, a second-generation N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer. ESMO Virtual Congress 2020. (Poster ID #11P).

    ESMO Virtual Congress 2020 Poster